Novabay Pharmaceuticals Stock Analysis
| NBY Stock | USD 0.61 0.01 1.61% |
NovaBay Pharmaceuticals is undervalued with Real Value of 1.38 and Target Price of 3.73. The main objective of NovaBay Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what NovaBay Pharmaceuticals is worth, separate from its market price. There are two main types of NovaBay Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The NovaBay Pharmaceuticals stock is traded in the USA on NYSE MKT Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. NovaBay Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. NovaBay Stock trading window is adjusted to America/New York timezone.
NovaBay |
NovaBay Stock Analysis Notes
About 14.0% of the company shares are owned by institutional investors. The book value of NovaBay Pharmaceuticals was now reported as 0.22. The company recorded a loss per share of 74.61. NovaBay Pharmaceuticals had not issued any dividends in recent years. The entity had 1:35 split on the 31st of May 2024. NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Novabay Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 29 people. To find out more about NovaBay Pharmaceuticals contact Justin Esq at 510 899 8800 or learn more at https://novabay.com.NovaBay Pharmaceuticals Investment Alerts
| NovaBay Pharmaceuticals has some characteristics of a very speculative penny stock | |
| NovaBay Pharmaceuticals had very high historical volatility over the last 90 days | |
| NovaBay Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 14.73 M. Reported Net Loss for the year was (9.64 M) with profit before taxes, overhead, and interest of 7.87 M. | |
| NovaBay Pharmaceuticals has about 5.36 M in cash with (4.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07. | |
| Latest headline from news.google.com: NovaBay Pharmaceuticals Share Price Passes Above 50-Day Moving Average Time to Sell - Defense World |
NovaBay Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by NovaBay Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
NovaBay Largest EPS Surprises
Earnings surprises can significantly impact NovaBay Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.3 | -0.33 | -0.03 | 10 | ||
2023-08-10 | 2023-06-30 | -0.56 | -0.64 | -0.08 | 14 | ||
2024-08-13 | 2024-06-30 | -1.23 | -1.37 | -0.14 | 11 |
NovaBay Market Capitalization
The company currently falls under 'Nano-Cap' category with a total capitalization of 3.28 M.NovaBay Profitablity
The company has Net Profit Margin of (0.73) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.43) %, which entails that for every $100 of revenue, it lost $0.43.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.23) | (1.29) | |
| Return On Capital Employed | (1.21) | (1.27) | |
| Return On Assets | (1.23) | (1.29) | |
| Return On Equity | (3.35) | (3.51) |
Management Efficiency
NovaBay Pharmaceuticals has Return on Asset of (0.418) % which means that on every $100 spent on assets, it lost $0.418. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.738) %, meaning that it generated no profit with money invested by stockholders. NovaBay Pharmaceuticals' management efficiency ratios could be used to measure how well NovaBay Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.29 in 2025. Return On Capital Employed is likely to drop to -1.27 in 2025. At this time, NovaBay Pharmaceuticals' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 463.4 K in 2025, whereas Other Assets are likely to drop slightly above 461.6 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 31.65 | 30.06 | |
| Tangible Book Value Per Share | 31.65 | 30.06 | |
| Enterprise Value Over EBITDA | (0.09) | (0.09) | |
| Price Book Value Ratio | 0.30 | 0.28 | |
| Enterprise Value Multiple | (0.09) | (0.09) | |
| Price Fair Value | 0.30 | 0.28 | |
| Enterprise Value | 540.3 K | 513.3 K |
NovaBay Pharmaceuticals' management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Technical Drivers
As of the 25th of March, NovaBay Pharmaceuticals secures the Downside Deviation of 5.01, mean deviation of 3.87, and Risk Adjusted Performance of 0.0534. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NovaBay Pharmaceuticals, as well as the relationship between them.NovaBay Pharmaceuticals Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. NovaBay Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for NovaBay Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
NovaBay Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NovaBay Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on NovaBay Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NovaBay Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NovaBay Pharmaceuticals Outstanding Bonds
NovaBay Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NovaBay Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NovaBay bonds can be classified according to their maturity, which is the date when NovaBay Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| NOVARTIS CAPITAL P Corp BondUS66989HAS76 | View | |
| NOVARTIS CAPITAL P Corp BondUS66989HAQ11 | View | |
| NOVARTIS CAPITAL P Corp BondUS66989HAR93 | View | |
| NOVARTIS CAP P Corp BondUS66989HAN89 | View | |
| NOVARTIS CAP P Corp BondUS66989HAK41 | View | |
| NOVARTIS CAP P Corp BondUS66989HAJ77 | View | |
| NOVARTIS CAP P Corp BondUS66989HAF55 | View | |
| NOVARTIS CAP P Corp BondUS66989HAH12 | View |
NovaBay Pharmaceuticals Predictive Daily Indicators
NovaBay Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NovaBay Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 0.61 | |||
| Day Typical Price | 0.61 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 48.23 |
NovaBay Pharmaceuticals Forecast Models
NovaBay Pharmaceuticals' time-series forecasting models are one of many NovaBay Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NovaBay Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About NovaBay Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how NovaBay Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling NovaBay shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as NovaBay Pharmaceuticals. By using and applying NovaBay Stock analysis, traders can create a robust methodology for identifying NovaBay entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.59) | (0.62) | |
| Operating Profit Margin | (0.31) | (0.32) | |
| Net Loss | (0.59) | (0.62) | |
| Gross Profit Margin | 0.62 | 0.80 |
Current NovaBay Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. NovaBay analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. NovaBay analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 3.73 | Strong Buy | 2 | Odds |
Most NovaBay analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand NovaBay stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of NovaBay Pharmaceuticals, talking to its executives and customers, or listening to NovaBay conference calls.
NovaBay Stock Analysis Indicators
NovaBay Pharmaceuticals stock analysis indicators help investors evaluate how NovaBay Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading NovaBay Pharmaceuticals shares will generate the highest return on investment. By understating and applying NovaBay Pharmaceuticals stock analysis, traders can identify NovaBay Pharmaceuticals position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 5.8 M | |
| Common Stock Shares Outstanding | 120.4 K | |
| Total Stockholder Equity | 3.3 M | |
| Property Plant And Equipment Net | 1.4 M | |
| Cash And Short Term Investments | 3.1 M | |
| Cash | 3.1 M | |
| Accounts Payable | 1.1 M | |
| Net Debt | -390 K | |
| 50 Day M A | 0.6554 | |
| Total Current Liabilities | 4.3 M | |
| Other Operating Expenses | 19.7 M | |
| Non Current Assets Total | 1.9 M | |
| Non Currrent Assets Other | 497 K | |
| Stock Based Compensation | 291 K |
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.